These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8643227)

  • 1. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer.
    Shiina H; Igawa M; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T
    Oncology; 1996; 53(3):233-40. PubMed ID: 8643227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
    Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of genetic instability with immunoreactivities for p53 protein and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Yagi H; Urakami S; Shirakawa H; Ishibe T
    Eur Urol; 1996; 30(1):80-8. PubMed ID: 8854073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological characteristics of inverted papilloma of the urinary bladder.
    Urakami S; Igawa M; Shirakawa H; Shiina H; Ishibe T
    Br J Urol; 1996 Jan; 77(1):55-60. PubMed ID: 8653317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage.
    Skopelitou A; Hadjiyannakis M; Dimopoulos D; Kamina S; Krikoni O; Alexopoulou V; Rigas C; Agnantis NJ
    Eur Urol; 1997; 31(4):464-71. PubMed ID: 9187909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 overexpression as a prognostic factor for advanced stage bladder cancer.
    Kuczyk MA; Bokemeyer C; Serth J; Hervatin C; Oelke M; Höfner K; Tan HK; Jonas U
    Eur J Cancer; 1995 Dec; 31A(13-14):2243-7. PubMed ID: 8652250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of nm23 protein in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Urakami S; Shirakawa H; Ishibe T
    Br J Urol; 1995 Dec; 76(6):708-13. PubMed ID: 8535713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
    Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
    Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].
    Offner FA; Schäfer G; Hittmair A; Ofner D; Grünewald K; Weyrer K; Mattern D; Eberle J; Mikuz G; Feichtinger H
    Verh Dtsch Ges Pathol; 1993; 77():241-6. PubMed ID: 7511289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].
    Kuczyk MA; Serth J; Bokemeyer C; Hervatin C; Oelke M; Oelert F; Höfner K; Jonas U
    Urologe A; 1995 Mar; 34(2):146-52. PubMed ID: 7754587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
    J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features.
    Lee CC; Yamamoto S; Morimura K; Wanibuchi H; Nishisaka N; Ikemoto S; Nakatani T; Wada S; Kishimoto T; Fukushima S
    Cancer; 1997 Feb; 79(4):780-9. PubMed ID: 9024716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder.
    Serth J; Kuczyk MA; Bokemeyer C; Hervatin C; Nafe R; Tan HK; Jonas U
    Br J Cancer; 1995 Jan; 71(1):201-5. PubMed ID: 7819040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?
    Doganay L; Altaner S; Bilgi S; Kaya E; Ekuklu G; Kutlu K
    Int Urol Nephrol; 2003; 35(2):181-8. PubMed ID: 15072490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
    Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
    Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.